AMG National Trust Bank Has $6.48 Million Position in Kenvue Inc. (NYSE:KVUE)

AMG National Trust Bank increased its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 8.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 280,095 shares of the company's stock after purchasing an additional 22,909 shares during the quarter. AMG National Trust Bank's holdings in Kenvue were worth $6,479,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. TrinityPoint Wealth LLC boosted its stake in Kenvue by 1.7% in the third quarter. TrinityPoint Wealth LLC now owns 60,490 shares of the company's stock valued at $1,399,000 after acquiring an additional 1,015 shares during the last quarter. Clarkston Capital Partners LLC boosted its stake in Kenvue by 0.5% in the third quarter. Clarkston Capital Partners LLC now owns 1,368,958 shares of the company's stock valued at $31,664,000 after acquiring an additional 7,164 shares during the last quarter. Swiss National Bank boosted its stake in Kenvue by 0.3% in the third quarter. Swiss National Bank now owns 5,683,346 shares of the company's stock valued at $131,456,000 after acquiring an additional 14,700 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Kenvue by 22.2% in the third quarter. Thrivent Financial for Lutherans now owns 4,186,599 shares of the company's stock valued at $96,836,000 after acquiring an additional 759,799 shares during the last quarter. Finally, Ceera Investments LLC boosted its stake in Kenvue by 3.1% in the third quarter. Ceera Investments LLC now owns 59,472 shares of the company's stock valued at $1,376,000 after acquiring an additional 1,810 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on KVUE shares. Deutsche Bank Aktiengesellschaft increased their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Piper Sandler raised their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research report on Monday, September 23rd. UBS Group lifted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Wednesday, August 7th. Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $22.64.

Kenvue Stock Performance

Kenvue stock traded down $0.09 during midday trading on Monday, hitting $23.73. The company's stock had a trading volume of 14,591,632 shares, compared to its average volume of 18,038,559. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.13. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a 50-day moving average price of $22.77 and a two-hundred day moving average price of $20.71. The company has a market cap of $45.50 billion, a price-to-earnings ratio of 43.24, a PEG ratio of 2.16 and a beta of 1.36.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. During the same quarter in the previous year, the company earned $0.31 EPS. The business's revenue was down .4% on a year-over-year basis. As a group, sell-side analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.46%. The ex-dividend date is Wednesday, November 13th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.